Soleus Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Soleus Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.3M	Sell	450,889 -999,026	-69%	-$34.4M	0.63%	44
2026 Q1	$45.7M	Buy	1,449,915 +539,915	+59%	+$15.6M	1.85%	14
2025 Q4	$22.6M	Buy	+910,000	New	+$18.3M	0.83%	37
2025 Q3	–	Sell	-76,493	Closed	-$1M	–	97
2025 Q2	$1M	Buy	76,493 +4,193	+6%	+$60.5K	0.07%	83
2025 Q1	$1.59M	Sell	72,300 -111,000	-61%	-$2.91M	0.11%	65
2024 Q4	$4.89M	Buy	+183,300	New	+$5.84M	0.31%	54
2021 Q4	–	Sell	-31,300	Closed	-$520K	–	79
2021 Q3	$520K	Hold	31,300	–	–	0.08%	72
2021 Q2	$668K	Sell	31,300 -68,700	-69%	-$1.88M	0.1%	62
2021 Q1	$3.25M	Buy	+100,000	New	+$3.24M	0.59%	37

Other funds holding EWTX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Soleus Capital Management's EWTX Position: Q2 2026 in Review

Soleus Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 69% in Q2 2026, selling an estimated $34.4M and leaving 450,889 shares worth $18.3M. The position accounts for 0.63% of the portfolio, ranked #44.

Soleus Capital Management first reported a position in EWTX in Q1 2021 and has held it in 9 quarters since. The position peaked at $45.7M in Q1 2026. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

Soleus Capital Management held 450,889 shares of Edgewise Therapeutics worth $18.3M as of Q2 2026.
Soleus Capital Management sold 999,026 Edgewise Therapeutics shares in Q2 2026, an estimated $34.4M.
Edgewise Therapeutics made up 0.63% of Soleus Capital Management's portfolio in Q2 2026, its #44 holding.
Soleus Capital Management first reported a position in Edgewise Therapeutics in Q1 2021 and has held it in 9 quarters since.
Soleus Capital Management's Edgewise Therapeutics position peaked at $45.7M in Q1 2026.
227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.